Navigation Links
Immune system implicated in prematurity complication
Date:3/19/2012

Despite advances in neonatal care, necrotizing enterocolitis (NEC) the most common gastrointestinal emergency in premature infants continues to be a deadly disease.

"We haven't made a lot of progress in identifying babies early who may be at risk for NEC, preventing it or treating it," said Jrn-Hendrik Weitkamp, M.D., a neonatologist and assistant professor of Pediatrics at Monroe Carell Jr. Children's Hospital at Vanderbilt.

Now, Weitkamp and his colleagues have discovered that disruptions in immune system regulation not previously considered to be important in NEC pathophysiology may play a role in the disease. The findings, reported in the journal Gut, suggest a new target for therapeutic interventions for NEC.

NEC is an inflammatory disease that kills intestinal tissue. Premature babies, and particularly those who have early formula feedings (breast milk has protective properties), are at increased risk for developing NEC.

About 40 percent of babies with NEC require surgery to remove dead bowel tissue and half of these babies do not survive. NEC survivors suffer long-term complications including bowel-related problems and impairments in motor and cognitive function.

Weitkamp wanted to explore whether differences in immune system regulation particularly in the "adaptive" immune response mediated by B cells and T cells might play a role in NEC. This type of cellular immunity was not considered important in the early neonatal period because it takes time to develop, and because it was not found in mouse models, Weitkamp said. But he knew from other studies that immune responses in newborn mice are not identical to immune responses in newborn humans.

Weitkamp and his colleagues turned to stored human intestinal tissue samples that had been surgically removed from preterm babies diagnosed with NEC or other intestinal diseases. They found high levels of T cells called T regulatory (Treg) cells in the i
'/>"/>

Contact: Leigh MacMillan
leigh.macmillan@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
2. UCI-led study uncovers how Salmonella avoids the bodys immune response
3. U of Alberta researcher steps closer to understand autoimmune diseases
4. Depression could be evolutionary byproduct of immune system
5. Secrets of immune response illuminated in new study
6. Human immune cells react sensitively to stress
7. Stealthy leprosy pathogen evades critical vitamin D-dependent immune response
8. Aiding cancer therapy by mathematically modeling tumor-immune interactions
9. UCSF team uncovers how immune cells move against invaders
10. La Jolla Institute researchers identify pivotal immune cell in Type 1 diabetes in humans
11. Researchers discover novel anti-viral immune pathway in the mosquito
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... long wondered if local animal cultures exist, and now, ... Primate Research Center at Emory University, the University of ... answer: Yes. , The study, available in today’s ... the capacity to sustain the same kind of multiple-tradition ...
... be living with Alzheimer’s disease in 2006, according to a ... of Public Health. The researchers also concluded the global prevalence ... by 2050. By that time, 43 percent of those with ... a nursing home. The findings were presented June 10 at ...
... in Northern Ireland since the early 1990s and are more ... more affluent areas, according to a study just published in ... who looked at official cancer statistics for nearly 23,000 patients ... in patients and a 62 per cent increase in skin ...
Cached Biology News:New collaborative research reveals chimpanzees can sustain multiple-tradition cultures 2Alzheimer's disease to quadruple worldwide by 2050 2Rising skin cancer rates are more likely to affect wealthy people, says 12-year review 2Rising skin cancer rates are more likely to affect wealthy people, says 12-year review 3
(Date:12/22/2014)... TENN (PRWEB) December 22, 2014 Fertility ... Donor Egg Bank USA , a network of ... country. Through this partnership, patients have fast access to ... in vitro fertilization, IVF . Fertility Associates of Memphis ... offer this fertility treatment option. , Dr. William ...
(Date:12/19/2014)... Dec. 19, 2014 Naurex Inc., a biopharmaceutical ... for diseases of the central nervous system, today announced ... executive officer, will present at the 33 rd ... take place at 3:00 p.m. PST on Tuesday, January ... San Francisco, Calif. ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fhh9rj/technology ... "Technology Innovations in Smart Fabrics (Technical Insights)" ... http://photos.prnewswire.com/prnh/20130307/600769 The Research Service ... detailed assessment on technological advancements and market for ... 1. The Smart Fabrics market is expected ...
(Date:12/19/2014)... Ed Bilsky, Ph.D., vice president for Research ... in the Neurosciences (CEN), and professor of pharmacology at ... a member of the prestigious Dana Alliance for Brain ... to receive this honor. , The Dana Alliance ... Dana Foundation. Its mission is to advance public ...
Breaking Biology Technology:Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Technology Innovations in Smart Fabrics (Technical Insights) 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3
... , , , ... (PTC) today announced the initiation of a Phase 2 clinical ... (NF2), a rare genetic disorder that causes the development of ... investigational new drug that is designed to selectively block tumor-related ...
... 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... of its contract manufacturer, SAFC Pharma(R), a Division of ... production run of REOLYSIN under cGMP conditions. This run ... to be completed over the next several years as ...
... , , CAMBRIDGE, Mass., ... and developing innovative treatments for pain, announced that David Julius, ... the University of California, San Francisco, and a leading pioneer ... board. , , "We admire Professor ...
Cached Biology Technology:PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 2PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 3PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 4Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R) 2Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board 2Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board 3
Request Info...
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Chicken polyclonal to ADI1 ( Abpromise for all tested applications). Antigen: Full length native protein (purified), corresponding to amino acids 1-179 of Human ADI1. Entrez GeneID: 55256 ...
Request Info...
Biology Products: